Is molotinib available on the market in China?

Molotinib, an innovative drug developed by the British company GlaxoSmithKline, is an important drug for the treatment of moderate or high-risk myelofibrosis. Especially for those adult patients with symptoms of anemia, molotinib has shown its unique efficacy.

Whether it is primary myelofibrosis or secondary myelofibrosis caused by polycythemia vera or essential thrombocythemia, molotinib can interfere with abnormal cell signaling in the disease through its specific mechanism, that is, inhibiting the activity of tyrosine kinases such asJAK1/JAK2, thus playing a therapeutic role. In clinical trials, the drug has been shown to significantly improve patients' anemia, reduce spleen enlargement, and improve patients' quality of life.

In addition, its safety has been confirmed in multiple studies, but patients still need to pay attention to possible side effects, such as thrombocytopenia or bleeding, and should strictly follow the doctor's instructions when using it. Overall, molotinib brings new therapeutic hope to patients with myelofibrosis, especially those with symptoms of anemia.

For patients who need molotinib, since the drug is not currently available in China, they need to purchase it through overseas channels. According to relevant information, the original version of molotinib is already available in overseas markets. Its specification is that each box contains 30 tablets of 100 mg each, and the price is as high as 220,000 yuan. At the same time, overseas markets also provide more affordable generic options for molotinib, such as the generic drug produced by Lucius Pharmaceuticals in Laos, which sells for less than 3,000 yuan. If patients have further consultation needs or questions about molotinib, they can seek help and answers from professional overseas medical consulting agencies.